Drugs / Famitinib
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | China (NMPA) | — | 宫颈癌 | — | “2025年9月，卡瑞利珠单抗联合法米替尼用于宫颈癌一线治疗的药品注册上市许可申请获国家药监局受理” hengrui.com ↗ |
Trials 73 · started per year
today
1
4
3
1
2
1
1
5
6
17
8
5
7
5
7
20092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT05473468 | Aug → Nov 2022 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05147727 | Mar → May 2022 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05103826 | Oct 2021 → Jun 2023 | estrogen-receptor positive breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05046808 | Sep → Oct 2021 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05041920 | Sep → Oct 2021 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04494659 | Jul → Aug 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02364362 | Jan 2015 → Dec 2018 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01462474 | Oct 2011 → Aug 2015 | nasopharyngeal carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01762280 | Jun 2009 → Apr 2012 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07662681 | Jul 2026 → Jul 2028 expected | head and neck cancer | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06332950 | Apr 2024 → Apr 2027 expected | small cell lung carcinoma | Baohui Han | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05176080 | Dec 2021 → Jul 2024 | breast cancer | Henan Cancer Hospital | Terminated | Mixed |
| Phase 1/2 | NCT05020925 | Sep 2021 → May 2022 | nasopharyngeal carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04679038 | Mar 2021 → Dec 2022 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04044378 | Aug 2019 → Sep 2021 | pediatric osteosarcoma | Peking University People's Hospital | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03805399 | Oct 2018 → Dec 2022 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 246 trials · 4 met primary | ||||||
| Phase 2 | NCT07847710 | Sep 2026 → Mar 2028 expected | intrahepatic cholangiocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07814859 | Aug 2026 → Aug 2027 expected | malignant pancreatic neoplasm | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07627620 | Jun 2026 → Sep 2027 expected | cervical cancer | Hunan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07517653 | Apr 2026 → Nov 2028 expected | melanoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07382713 | Feb 2026 → Dec 2030 expected | ovarian cancer | Jinhua Zhou | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07355010 | Dec 2025 → Dec 2028 expected | ovarian cancer | Qinglei Gao | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07143292 | Nov 2025 → Dec 2026 expected | cervical cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07796113 | Oct 2025 → Oct 2028 expected | esophageal squamous cell carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Recruiting | No outcome recorded |
| Phase 2 | NCT07147088 | Sep 2025 → Sep 2027 expected | intrahepatic cholangiocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06649331 | Oct 2024 → Sep 2026 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06516289 | Sep 2024 → Jun 2026 overdue | Her2-receptor negative breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07309185 | Jul 2024 → Jul 2027 expected | gastric neoplasm | Shandong Tumor Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06336954 | Mar → Jul 2024 overdue | non-small cell lung carcinoma | Second Affiliated Hospital of Xi'an Jiaotong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06306560 | Mar 2024 → Mar 2027 expected | small cell lung carcinoma | Harbin Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06332300 | Feb 2024 → Feb 2025 | non-small cell lung carcinoma | Jiangsu Province Nanjing Brain Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT06146985 | Dec 2023 → Nov 2024 | thyroid cancer | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05749588 | Mar 2023 → Dec 2027 expected | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05670925 | Mar → Sep 2023 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05594095 | Dec 2022 → Dec 2025 overdue | female breast carcinoma, hormone receptor-positive breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05582499 | Nov 2022 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05214976 | Aug 2022 → Jan 2023 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05208177 | Apr 2022 → Aug 2023 | neoplastic disease or syndrome | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05051865 | Oct 2021 → Aug 2024 | melanoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 2 | NCT05005468 | Sep 2021 → Aug 2023 | non-small cell lung carcinoma | Shanghai Chest Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04888429 | Jul 2021 → Dec 2024 overdue | lung sarcomatoid carcinoma | Qian Chu | Recruiting | No outcome recorded |
| Phase 2 | NCT04884009 | May 2021 → Dec 2022 | lung cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04733417 | May 2021 → Aug 2022 | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04814485 | Apr 2021 → Jul 2023 | malignant pancreatic neoplasm | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04680988 | Apr 2021 → Jul 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | Met primary |
| Phase 2 | NCT04866381 | Apr 2021 → Apr 2023 | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04699968 | Jan → Nov 2021 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04479904 | Aug 2020 → Dec 2021 | intrahepatic cholangiocarcinoma | Jiangsu HengRui Medicine Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04395989 | Jul 2020 → May 2023 | triple-negative breast carcinoma | Fudan University | Unknown | Met primary |
| Phase 2 | NCT04346381 | Jun 2020 → Jun 2022 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04355858 | May 2020 → May 2023 | breast cancer, metastatic malignant neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT04521348 | Dec 2019 → Dec 2024 | thyroid cancer | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT04129996 | Oct 2019 → Sep 2022 | triple-negative breast carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT03904823 | Apr 2019 → Dec 2022 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03827837 | Jan 2019 → Dec 2022 | cervical cancer, endometrial cancer, ovarian carcinoma, renal cell carcinoma +1 | Jiangsu HengRui Medicine Co., Ltd. | Unknown | Met primary |
| Phase 2 | NCT02356991 | Dec 2014 → Jun 2020 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Suspended | No outcome recorded |
| Phase 2 | NCT01653574 | May 2012 → Nov 2013 | breast neoplasm | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT01762293 | Apr 2012 → Sep 2014 | colorectal cancer | Jiangsu HengRui Medicine Co., Ltd. | Completed | Met primary |
| Phase 2 | NCT02336724 | Mar 2012 → Dec 2018 | gastrointestinal stromal tumor | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT01994213 | Oct 2011 → Nov 2015 | digestive system neuroendocrine neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT01392235 | Jul 2011 → Apr 2015 | nasopharyngeal carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01829841 | May 2011 → Apr 2013 | renal cell carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 311 trials · 1 met primary | ||||||
| Phase 3 | NCT07382687 | Feb 2026 → Dec 2028 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06913777 | Apr 2025 → Oct 2026 expected | — | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05999149 | Aug 2023 → Aug 2025 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05760378 | Mar 2023 → Jan 2025 overdue | triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05042375 | Sep 2022 → Dec 2023 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05106335 | Jan → May 2022 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT04906993 | Jul 2021 → Jun 2025 overdue | cervical cancer | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | Met primary |
| Phase 3 | NCT04619433 | Feb 2021 → Aug 2025 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT04409223 | Sep 2020 → Mar 2022 | gastrointestinal stromal tumor | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT02766140 | Jun → Nov 2016 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02390947 | Jan 2015 → Feb 2019 | metastasis from malignant tumor of colon | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-24 | Jiangsu HengRui Medicine Co., Ltd. | Results 2025 ESMO口头报告｜恒瑞创新药法米替尼联合卡瑞利珠单抗用于复发/转移性宫颈癌一线治疗数据重磅公布 hengrui.com ↗
本研究的主要终点分析显示，卡瑞利珠单抗-法米替尼治疗组较化疗组显著延长了PFS和OS。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-10-24 | Jiangsu HengRui Medicine Co., Ltd. | 2025 ESMO口头报告｜恒瑞创新药法米替尼联合卡瑞利珠单抗用于复发/转移性宫颈癌一线治疗数据重磅公布 hengrui.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 76 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | famitinib | “Adibelimab (1200mg, IV, every 3 weeks) combined with Famitinib (20mg, daily, orally) and Albumin-bound Paclitaxel (260mg/m2, Day 1, every 3 weeks)” NCT06336954 ↗66“famitinib plus anti-PD-1 antibody could advance TLS in thyroid cancer.” PMID 38478516 ↗ Mar 2024 “and famitinib 20mg qd continuously” NCT03805399 ↗ |
| Known as | C1: PD-1 with nab-paclitaxel and famitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04395989 ↗ |
| Known as | Famitinib Malate | “Famitinib Malate Capsules 10mg single dose” NCT05046808 ↗4“famitinib malate, 25 mg on study day 1” NCT05041920 ↗ “Famitinib malate capsules, 20 mg” NCT05042375 ↗ “Famitinib malate capsules, qd.” NCT05208177 ↗ |
| Known as | SHR1020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02766140 ↗ |
| Action | Inhibit | “tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3” NCT01392235 ↗1“Vascular endothelial growth factor receptor 3 inhibitor” CHEMBL1278146 ↗ |
| Modality | Small molecule | “Famitinib is a small-molecule multikinase inhibitor” PMID 29273089 ↗ Dec 2017 |
| Route | Oral | “25 mg qd p.o.” NCT01392235 ↗ |
| Target | FLT4 | “Vascular endothelial growth factor receptor 3 inhibitor” CHEMBL1278146 ↗ |
| Target | KDR | “Famitinib is an inhibitor of multiple tyrosine kinases mainly targeting VEGFR-2.” PMID 24939214 ↗ Jun 2014 |